What our clients say
Ichor’s executive team has a unique talent for creative problem-solving and a goal-oriented approach to research. They have built and led several highly effective research initiatives for SENS Research Foundation, with a consistent focus on value creation and actionable endpoints.
Ichor has redefined effective implementation and quality assurance since I began working with them in 2014. Their emphasis on understanding project requirements, coupled with rigorous method development, elevate them head and shoulders above other CROs in the space.
Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results
Ichor builds new partnerships and lands $600k investment for its Age-related Macular Degeneration (AMD) research initiative, which has shown positive early results. Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many as 15 million Americans and millions more globally. AMD has a significant impact […]
In March we signed on a new investor, Roger Bagg (you may have seen our press release over at MedTech, or the Town of Lafayette Newsletter – we’re glad everyone else was as excited as we were!). Roger is an ideal investor for Ichor. He has experience investing in other Biotech firms both in the US and the UK, […]
FOR IMMEDIATE RELEASE LaFayette, New York, March 2nd, 2016 Ichor Therapeutics, a local biotechnology company focusing on therapeutic interventions for age-related disease, receives $1.35 million in new funding — including $1 million from European investors — and begins a 4-fold expansion of research capabilities in LaFayette, NY to engage in FDA compliant pre-clinical research. Ichor was […]